![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 7, 2024
This cancer care delivery study aims to provide out-of-pocket cost estimates and remote counseling to assist patients in navigating the financial aspects of cancer treatment
March 7, 2024
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
December 19, 2023
This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
December 19, 2023
This cancer care delivery study aims to improve medication adherence for patients with HR+/HER2- metastatic breast cancer
December 19, 2023
These four lung cancer treatment trials are all open and enrolling patients
October 19, 2023
Through a series of blood tests and patient questionnaires, this prospective observational study examines how exposures to trauma and other adverse life experiences alter the activity of genes, immune cells, and subsequent health outcomes
October 19, 2023
This randomized phase 3 trial explores repeated focused radiation to control disease and spare patients with renal cell carcinoma from systemic therapy for months or even years
October 19, 2023
This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
October 19, 2023
These four leukemia treatment trials and an observational study of myelodysplastic syndromes are all open and enrolling patients
August 25, 2023
This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy